[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588151":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":59,"collaborators":62,"id":65,"slug":25,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":25,"enrollmentInfo":73,"targetDuration":25,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":25,"overallStatus":38,"whyStopped":25,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Beth Israel Deaconess Medical Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Guideline-based Care","ACTIVE_COMPARATOR","Remote monitoring programming scheduled for alert transmissions, patient-initiated transmissions, and routine transmissions (scheduled to occur every 90 days from the date of enrollment in the study); in-office interrogations on at least an annual basis",[13],"Device: Guideline-based care",{"label":15,"type":10,"description":16,"interventionNames":17},"Alert-based Care","Remote monitoring programming scheduled for alert transmissions and patient-initiated transmissions only",[18],"Device: Alert-based care",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","Alert-based care","Alert-based care is an alternative strategy for longitudinal management of patients with wireless pacemakers and implantable defibrillators",[15],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Guideline-based care","Guideline-based care is the current typical standard for longitudinal management of patients with wireless pacemakers and implantable defibrillators",[9],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Linda Valsdottir, MS","CONTACT","6176678800","lvalsdot@bidmc.harvard.edu",[37],{"facility":5,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"RECRUITING","Boston","Massachusetts","02215","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-71.05977,42.35843,{"lat":48,"lon":47},[51,55,57],{"name":52,"role":33,"phone":53,"phoneExt":25,"email":54},"Daniel B Kramer, MD","617-667-8800","dkramer@bidmc.harvard.edu",{"name":32,"role":33,"phone":56,"phoneExt":25,"email":35},"617-632-7652",{"name":52,"role":58,"phone":25,"phoneExt":25,"email":25},"PRINCIPAL_INVESTIGATOR",{"type":58,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Daniel B. Kramer","Associate Professor of Medicine",[63],{"name":64,"class":6},"Patient-Centered Outcomes Research Institute","100588151",false,"NCT06937658","Remote Alert Pathway To Optimize CaRe of Cardiac Implantable Electrical Devices","RAPTOR-CIED","Inclusion Criteria:\n\n1. Adult aged \\> 18 years\n2. Clinically stable by investigator assessment\n3. Has a newly implanted or existing wireless CIED: single, dual-chamber, biventricular, subcutaneous\u002Fextravascular, and leadless systems are all eligible, including pacemakers or implantable cardioverter-defibrillators (ICDs)\n4. CIED is from one of the 4 major CIED manufacturers in the US market (99% of implants in the US): Medtronic, Boston Scientific, Abbott, Biotronik\n5. Currently enrolled in remote monitoring as part of standard of care\n6. Primary clinical electrophysiology follow-up at the enrolling center\n7. Understands spoken and written English, Spanish, or Portuguese\n8. Has sufficient cognitive function to answer standardized questions about study rationale and procedures.\n\nExclusion Criteria:\n\n1. Presence of insertable cardiac monitor, either in isolation or in combination with any other CIED\n2. Listed for cardiac transplantation prior to enrollment (N.B. if a patient becomes listed for transplantation during the study, they may continue study participation)\n3. Participation in another study related to novel CIED technology or remote monitoring.","ALL","18 Years",{"count":74,"type":75},120,"ESTIMATED","INTERVENTIONAL",[78],"NA","The Remote Alert Pathway to Optimize Care of Cardiac Implantable Electrical Devices (RAPTOR-CIED) Study is a pragmatic, multi-center, randomized trial with 1:1 patient-level randomization comparing the safety and effectiveness of alert-driven care versus guideline-based care for patients with wireless cardiac implantable electrical devices (CIEDs).\n\nThe study will be conducted in 2 phases: a Feasibility Phase and a Main Phase. This registration outlines the goals and design features of the Feasibility Phase of the study.",[81,82],"Pacemaker DDD","Implantable Defibrillator User","2026-01-05",{"date":85,"type":86},"2026-01-07","ACTUAL",{"date":88,"type":86},"2025-05-01",{"date":90,"type":75},"2026-06-30",{"name":5,"class":6},1]